Perceptive Advisors Acquires Synthego
July 18, 2025
Funds managed by Perceptive Advisors have acquired substantially all of the assets of Synthego, with the transaction closing on July 18, 2025. Synthego will continue operating under its existing leadership and brand, maintaining manufacturing of guide RNA in Redwood City while leveraging Perceptive's resources to accelerate product development and expand its CRISPR offerings.
- Buyers
- Perceptive Advisors
- Targets
- Synthego
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Riverside Partners Combines Sequoia Biotech Consulting and Syner-G BioPharma Group
September 18, 2024
Healthcare Services
Boston-based private equity firm Riverside Partners has combined two of its portfolio companies, Sequoia Biotech Consulting and Syner-G BioPharma Group, into a single, integrated life‑sciences services business. The combined organization — bringing together regulatory, development, quality, and operational capabilities — has approximately 500 employees and will provide end-to-end solutions to pharmaceutical, biotechnology, and medical device clients.
-
Summa Equity Acquires Majority Stake in Sengenics
October 14, 2020
Biotechnology
Summa Equity Fund II has acquired a majority stake in Sengenics, a functional proteomics company that commercialises the KREX technology for full‑length, correctly folded protein production and autoantibody detection. The investment will support Sengenics' product development, global expansion and accelerated commercial adoption across pharma, academic research and diagnostics.
-
Paragraf Acquires Cardea Bio
May 3, 2023
Biotechnology
Paragraf, Ltd. has acquired Cardea Bio, the developer of the graphene-based CRISPR-Chip that powers CRISPR QC's CRISPR Analytics Platform. The acquisition combines Paragraf's scalable graphene electronics manufacturing with Cardea's biosensor expertise to secure a reliable supply of CRISPR-chips and accelerate deployment of CRISPR Analytics capabilities across the gene‑editing and life‑sciences markets.
-
Syneos Health Acquires Synteract from Amulet Capital Partners
December 10, 2020
Healthcare Services
Syneos Health (NASDAQ: SYNH) has completed the acquisition of Synteract, a full-service contract research organization (CRO) focused on emerging biopharma. The seller was Amulet Capital Partners, which had previously built Synteract through organic investment and add-on acquisitions.
-
Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities
July 11, 2023
Biotechnology
Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.
-
AlphaSense Acquires Sentieo
May 11, 2022
Data & Analytics
AlphaSense has acquired Sentieo, a financial intelligence platform for the investment management industry. The acquisition expands AlphaSense's product capabilities and content offerings while adding over 1,000 customers (including 800+ institutional investment firms) to its base.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.